ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Primary non-hepatoblastoma liver tumors in children-Defining the profile of a very rare subset of childhood tumors.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary pediatric non-hepatoblastoma (n-HB) liver tumors are rare with limited literature on their clinical-epidemiological profile and outcomes. We audit the above in this study.
methodsChildren diagnosed with n-HB primary liver tumors from January 2012 to December 2023 were analyzed retrospectively. Patients underwent contrast-enhanced computed tomography (CECT) of the abdomen and computed tomography (CT) of the thorax or fluorodeoxyglucosepositron emission tomography/computed tomography (FDG-PET/CT) for staging of malignant tumors. Treatment was administered based on the definitive diagnosis.
resultsSixty-nine patients formed the study cohort. The most common tumors in various age groups were infantile hepatic hemangioma (IHH)-66.7%, malignant rhabdoid tumor (MRT)-25%; six months to three years: MRT-25.0%, mesenchymal hamartoma and hemangioendothelioma-18.7% each; three to 10 years: hepatocellular carcinoma (HCC)-31.6%, undifferentiated embryonal sarcoma of the liver (UESL)-26.3%; and > = 10 years: HCC-45.4%, UESL-22.7%. Median alpha-fetoprotein (AFP) level in HCC was 131,249 ng/mL. Treatment was delivered to 65.8% patients. Chemotherapy for treated malignant tumors was administered in 81.5%, surgery in 85.2% and radiotherapy in 18.5%, alone or combined. In the different malignant cancer sub-types, the proportion of relapse/deaths in treated patients was HCC-22.2%, UESL-33.3%, rhabdoid-25%, hemangioendotheliomas-25% and sarcomas-25%.
conclusionsThere was a high proportion of malignant rhabdoid tumors and higher serum AFP levels in HCC in our cohort. The overall outcomes of treated malignant tumors were relatively favorable, though limited by the sample size in this rare cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.